Once-weekly insulin
Basal insulins given once a week, such as insulin icodec.
Key point
No clinically relevant differences were observed in hypoglycemic event duration or characteristics between once-weekly efsitora and once-daily basal insulin groups.
From: Duration and characteristics of hypoglycemia with once-weekly insulin efsitora alfa versus once-daily basal insulins in adults with type 2 diabetes: Exploratory safety analysis of QWINT 2-4 (Diabetes Res Clin Pract, 2026 Sep) ↗Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 7, 5, 4, 6, 5.
All papers from the last 12 months
67 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Insulin Efsitora Demonstrates Similar Efficacy and Safety Profiles to Insulin Icodec in Insulin-Experienced Individuals With Type 2 Diabetes Mellitus: Matching-Adjusted Indirect Comparisons of QWINT-3 Versus ONWARDS 2, and QWINT-4 Versus ONWARDS 4Diabetes Obes Metab2026 NovPMID 42680157RCT
- Hospitalization outcomes in adults with type 2 diabetes mellitus treated with once-weekly insulin efsitora versus once-daily basal insulins: A post hoc analysis of the QWINT-1 to -4 randomized trialsDiabetes Res Clin Pract2026 Oct 3PMID 42829184
- Once-weekly IcoSema versus once-daily insulin glargine U100 in type 2 diabetes management (COMBINE 4): an open-label, multicentre, treat-to-target, randomised, phase 3b trialLancet Diabetes Endocrinol2026 OctPMID 42594928RCT
- Efficacy and Hypoglycaemia Outcomes With Once-Weekly IcoSema Versus Comparators in Individuals With Type 2 Diabetes by Kidney and Liver Function: A Post Hoc Analysis of the COMBINE 1-3 TrialsDiabetes Obes Metab2026 OctPMID 42557064RCT
- Projecting the Long-Term Cost-Effectiveness of Once-Weekly Insulin Icodec Versus Once-Daily Basal Insulin Analogs in Italy Using the Prime T2D ModelDiabetes Obes Metab2026 OctPMID 42538099
- Pharmacokinetics, Pharmacodynamics, and Safety of Once-Weekly Insulin Efsitora Alfa in Chinese Patients with Type 2 Diabetes: A Phase 1 Open-Label, Randomized, Active-Controlled TrialAdv Ther2026 OctPMID 42423945RCT
- Once-Weekly Insulin Icodec: Safety Profile in Type 2 and Type 1 Diabetes Based on a Pooled Analysis of ONWARDS 1-6Endocr Pract2026 OctPMID 42119975
- The Effect of Intrinsic Factors on the Pharmacokinetics of Once-Weekly Insulin Icodec in Type 1 and Type 2 Diabetes: A Population Pharmacokinetic Analysis of Phase II and Phase III trialsClin Pharmacokinet2026 Sep 30PMID 42814374
- Once-weekly insulin icodec (Awiqli) for type 2 diabetesMed Lett Drugs Ther2026 Sep 28PMID 42752391
- Use of Continuous Glucose Monitoring Indicators to Guide Dose Titration of Weekly Basal Insulin Efsitora Alfa in Insulin-Naive and Basal Insulin-Experienced Adults with Type 2 Diabetes: A Retrospective AnalysisDiabetes Technol Ther2026 Sep 17PMID 42751863
More endocrinology trends
All specialties →Menopausal hormone therapy
Hormone therapy for menopausal symptoms, benefits and risks.
Thyroid eye disease
Thyroid eye disease and targeted treatments such as teprotumumab.
Key point: IGF-1R inhibitors outperformed placebo across multiple thyroid eye disease efficacy outcomes, particularly in active disease, but increased adverse-event risk warrants vigilant monitoring.
CGM in type 2 diabetes
Continuous glucose monitoring for people with type 2 diabetes.
Key point: CGM is strongly recommended for people with type 2 diabetes treated with insulin and those not treated with insulin, particularly when HbA1c is ≥7%.
Anabolic osteoporosis treatment
Romosozumab, abaloparatide and teriparatide for osteoporosis.
Key point: Abaloparatide has efficacy and safety similar to teriparatide and represents a new option for patients with severe osteoporosis and very high fracture risk.
Cell therapy for type 1 diabetes
Islet transplantation and stem cell-derived beta cells.
Delaying type 1 diabetes
Teplizumab and other immunotherapy to delay type 1 diabetes.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
"insulin icodec"[tiab] OR "insulin efsitora"[tiab] OR "once-weekly insulin"[tiab]Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.